Cleveland Diagnostics

PSA on PSA: Supporting Prostate Cancer Awareness in September

This month, Cleveland Diagnostics, developer of the IsoPSA Test, has relaunched the PSA on PSA Campaign for Prostate Cancer Awareness Month.

Short for a Public Service Announcement on the Prostate-Specific Antigen (PSA) test, the national campaign raises awareness of prostate cancer risk and encourages informed conversations about screening and testing.

Learn More

This year's campaign will introduce On Call for Men's Health: A PSA on PSA, a limited video series featuring candid conversations with leaders in urology, prostate cancer, and men's health.

September | Prostate Cancer Awareness Month.

The series was created in partnership with Michigan Men's Health Foundation to spark more open conversations about men's health.

New episodes will be released weekly throughout September covering topics that shape men's health outside the exam room, including fear, access to care, mental health, and more.

Share the PSA on PSA campaign with your family, friends, and patients to support prostate cancer awareness this September.

Guiding the Next Step After an Elevated PSA

For men over 50 years of age with elevated PSA, the IsoPSA Test can support improved risk stratification for clinically significant prostate cancer (csPCa).¹

An extensive body of published research has demonstrated the test's ability to enhance biopsy decision-making¹, clarify PI-RADS 1-3 results², and predict risk for csPCa over time.³

Subscribe to learn more and receive updates when educational content, including CME programs and case studies, is available.

Klein, et al., Urol Oncol. 2022 Sep;40(9):408.e9 408.e18.
Benidir et al., Urology. 2023 Jun;176:115 120
Abdallah, et al., Urology Jan15:S0090 4295(25)00031 7.

This material concerns the IsoPSA Test, a laboratory developed test (LDT) from Cleveland Diagnostics, Inc., which is performed by CLIA-certified laboratories qualified to conduct high-complexity clinical testing and is only intended for use consistent with applicable CLIA requirements. When offered as an LDT, the IsoPSA Test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).